PEDRO
PÉREZ SEGURA
Profesor asociado de Ciencias de la Salud
![Foto de PEDRO](/img/nophoto.png)
![Foto de Institute Catalá Oncología](/img/noimage_org.png)
Institute Catalá Oncología
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Institute Catalá Oncología (26)
2024
-
A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma
Journal of Neuro-Oncology, Vol. 166, Núm. 3, pp. 407-415
-
Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma (Journal of Neuro-Oncology, (2024), 166, 3, (407-415), 10.1007/s11060-023-04513-1)
Journal of Neuro-Oncology
2023
-
What do patients and oncologists think about the evaluation and management of cancer-related anorexia-cachexia? The Quasar_SEOM study
Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3479-3491
2022
-
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores
Journal of the National Cancer Institute, Vol. 114, Núm. 1, pp. 109-122
-
Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers
Communications biology, Vol. 5, Núm. 1, pp. 1061
-
Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial
Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661
-
Erratum: Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (European journal of human genetics : EJHG (2022) 30 3 (349-362))
European journal of human genetics : EJHG
-
Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
Frontiers in Oncology, Vol. 12
-
Polygenic risk modeling for prediction of epithelial ovarian cancer risk
European journal of human genetics : EJHG, Vol. 30, Núm. 3, pp. 349-362
2020
-
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
Neuro-oncology, Vol. 22, Núm. 12, pp. 1851-1861
2018
-
Correction to: SEOM clinical guidelines for anaplastic gliomas (2017) (Clinical and Translational Oncology, (2018), 20, 1, (16-21), 10.1007/s12094-017-1762-7)
Clinical and Translational Oncology
-
SEOM clinical guidelines for anaplastic gliomas (2017)
Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 16-21
2017
-
Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification
Neuro-Oncology, Vol. 19, Núm. 11, pp. 1522-1531
2016
-
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma
Anti-Cancer Drugs, Vol. 27, Núm. 2, pp. 133-137
2015
-
A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma
Clinical and Translational Oncology, Vol. 17, Núm. 9, pp. 743-750
-
Candidate genetic modifiers for breast and ovarian cancer risk inBRCA1andBRCA2 mutation carriers
Cancer Epidemiology Biomarkers and Prevention, Vol. 24, Núm. 1, pp. 308-316
-
Mammographic density and breast cancer in women from high risk families
Breast Cancer Research, Vol. 17, Núm. 1
2014
-
Erratum: Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry [J Neurooncol, 116, (2014), 413-419, DOI 10.1007/s11060-013-1316-y]
Journal of Neuro-Oncology
-
Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers
Breast Cancer Research and Treatment, Vol. 148, Núm. 2, pp. 415-421
2012
-
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO)
Anti-Cancer Drugs, Vol. 23, Núm. 6, pp. 659-665